Navigation Links
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Date:6/2/2009

ANNAPOLIS, Md., June 2 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats. PharmAthene has requested funding to further develop Valortim(R), a fully human monoclonal antibody, for the prevention and treatment of anthrax infection. To date, the Company has received funding commitments from the U. S. government totaling up to $24 million to advance the development of Valortim(R).

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "We look forward to BARDA's decision regarding our funding proposal for the advanced development of Valortim(R). We believe that Valortim(R) may have important competitive advantages, including a novel mechanism of action, which, if demonstrated, would make it a strong choice for procurement consideration in the Strategic National Stockpile (SNS). Additional funding will allow us to complete clinical and non-clinical efforts through pivotal safety and efficacy studies, and to perform cGMP and conformance lot manufacturing. If successful, Valortim(R) may be eligible for acquisition into the SNS for potential use under an Emergency Use Authorization (EUA), and for submission of a Biologics License Application (BLA)."

About Valortim(R)

Valortim(R) is a fully human monoclonal antibody generated by Medarex, Inc's UltiMAb(R) technology that is being co-developed by the two companies and is designed to protect against and treat anthrax infection, including inhala
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
2. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... FALLS, N.J. , May 1, 2015 CANTEL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at the Encore at the Wynn in Las ... Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ET. ... during the day. An audio webcast will ...
(Date:5/1/2015)... , May 1, 2015  Portal Instruments, Inc., ... delivery systems, announced today that Robert Langer, Sc. ... Ph.D., University of Auckland Distinguished Professor have joined the ... to welcome two esteemed biotechnology leaders, Professor Robert ... our team," said Dr. Patrick Anquetil , Chief ...
(Date:5/1/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world leader in ... hearts, announced today that Marta Antonucci has joined ... This new Europe -based position is ... North America , including Europe , ... , and reports directly to the Chief Executive Officer. Following ...
Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
... 1, 2011 Milestone Scientific Inc. (OTCQB: MLSS), the ... the Company filed its 2010 year-end results for the ... Securities & Exchange Commission on Wednesday, March 30, 2011. ... teleconference Monday, April 4, 2011 beginning at 4:15 PM ...
... 2011 New data presented today at the 46th ... of the Liver (EASL) demonstrate the antiviral activity of ... both treatment-naive and -experienced patients with chronic genotype-1 (GT1) ... HCV to treat.  Results from SILEN-C1 show a sustained ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 2Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 3Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 4Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 5Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients 6
(Date:5/2/2015)... Beach, FL (PRWEB) May 02, 2015 ... has selected The Delray Recovery Center as one of ... Center is known in the addiction treatment field for ... staff members to innovate and to continue their educational ... a positive workplace environment, never forgetting their purpose – ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare ... its new healthcare insurance to individuals and small businesses ... System is the nation’s first health insurance system built ... Personal Health Insurance was ZoomCare’s first such filing including ... to review and regulation by the Oregon Insurance Division. ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
(Date:5/1/2015)... 2015 Hope For The Warriors® thanks ... For The Warriors® and military families. All American Ford ... For The Warriors®, a national nonprofit dedicated to restoring ... restoring hope for our service members and our military ... Ford collected and matched small autograph fee from fans ...
(Date:5/1/2015)... Colorado (PRWEB) May 01, 2015 As ... States approaches its 18-month anniversary, many people in the ... been achieved. , According the latest annual report by ... expanded 74 percent in 2014, and reached nearly $3 ... America’s decades-long love affair with cannabis, combined with the ...
Breaking Medicine News(10 mins):Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3
... Feb. 12 Bunker Hill Community College is ... held a series of events on National Wear Red Day ... disease is the leading cause of death in women. Stickers ... campaign - were handed out to the entire College community, ...
... Feb. 12 Medicare now pays for treatments deemed ... that and apply a cost-effectiveness standard set by a ... Research.The Federal Council is modeled after a U.K. board ... This British board approves or rejects treatments using a ...
... as likely to show early damage, and study says it,s likely ... who consume two or more cans of soda pop daily are ... evidence of kidney disease, according to a U.S. study. , But ... pop or for people who drink diet soda. , The researchers ...
... Slumdog Millionaire show the challenges facing the polio eradication ... Oscar-watchers are getting a short course in polio eradication ... show the status of this paralyzing disease in India ... virus has not been stopped. The Final Inch, ...
... ISTA ), today announced it will release fourth quarter and ... a conference call to discuss these results and provide a pipeline ... Date: Thursday, February 19, 2009, ... Internet: www.istavision.com, Domestic dial-in: 866-730-5766, ...
... who as children got radiation treatment for Hodgkin,s disease are ... cancer, according to findings from five institutions, including the University ... higher the risk, researchers report. These women are also likely ... is always to get rid of the cancer. Our second ...
Cached Medicine News:Health News:Bunker Hill Community College Celebrates 'Wear Red Day' 2Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3
... information to facilitate diagnostic accuracy for appropriate ... sterile, disposable device used to inject fluid ... procedures. The device will measure the pressure ... a digital format. The physician can control ...
Maxi-Therm® hyper-hypothermia water blankets from Cincinnati Sub-Zero are designed for single-patient use. These blankets are easy to clean, stain resistant and ideal for isolation cases....
The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
The ImmunoWELL Borrelia M Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi,IgM antibodies in serum and is used as an aid in the diag...
Medicine Products: